Ranking Ajax's $95 Million Series C Against Its Eventual $2.3 Billion Exit Value

Ajax Therapeutics offers a striking example of how quickly private biotech valuations can change when a promising clinical asset attracts strategic interest from a major pharmaceutical company. The company raised $95 million in an oversubscribed Series C financing in June 2024, with the funding intended to advance its lead JAK2 inhibitor, AJ1-11095. Less than two years later, Eli Lilly agreed to acquire Ajax for up to $2.3 billion, creating a dramatic contrast between its last major private financing and eventual exit value.

From $95 Million Funding to a Multibillion-Dollar Exit

The difference between the two figures illustrates the premium pharmaceutical companies can place on promising clinical-stage assets. Ajax's Series C valued the company at a stage when its lead program was still being developed, while Lilly's acquisition came after AJ1-11095 had entered clinical testing. Lilly announced the deal in April 2026, with the total consideration structured around an upfront payment and additional clinical and regulatory milestones.

AJ1-11095 Was the Main Attraction

The central asset behind the transaction is AJ1-11095, an investigational once-daily oral JAK2 inhibitor designed to target a different binding mechanism from existing JAK2 treatments. The drug was being evaluated in patients with myelofibrosis who had previously received another JAK2 inhibitor. Lilly's interest reflects the potential for a next-generation treatment to address patients who lose response to existing therapies.

Lilly's Broader Oncology Buying Strategy

The Ajax transaction also fits into Lilly's broader 2026 strategy of expanding its oncology pipeline through acquisitions. The company had already pursued several biotech deals, including acquisitions involving Scorpion Therapeutics, Orna Therapeutics and Kelonia Therapeutics, as it looked to diversify beyond its highly successful diabetes and obesity franchises. Ajax therefore represents another example of Lilly using M&A to acquire promising external innovation rather than relying entirely on internal R&D.

What the Valuation Jump Actually Tells Investors

The headline comparison should nevertheless be interpreted carefully. The $2.3 billion figure is a potential total value, not necessarily an upfront cash payment, because part of the consideration depends on future clinical and regulatory milestones. That makes the transaction less comparable to a simple $2.3 billion cash valuation. Still, the gap between the $95 million Series C and the potential acquisition value demonstrates how rapidly biotech assets can appreciate when clinical development reduces some of the uncertainty surrounding a drug candidate.

A Useful Benchmark for Biotech M&A

Ajax's trajectory provides a useful benchmark for the broader 2026 biotech M&A market, where pharmaceutical companies are increasingly willing to acquire relatively early-stage assets to strengthen future pipelines. Reuters reported that biotech M&A reached $84 billion in Q1 2026, nearly twice the level of the same period a year earlier. Ajax therefore fits into a much larger trend in which big pharmaceutical companies are paying significant premiums for promising clinical programs rather than waiting for those assets to reach late-stage development.